Search

Displaying results 3951 - 3960 of 7503 in total
  1. Drug

    Atigliflozin

    go.drugbank.com/drugs/DB21394
    Investigational

    Atigliflozin is under investigation in clinical trial NCT00361738 (Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment).

  2. Drug

    Camostat

    go.drugbank.com/drugs/DB13729
    Investigational

    [A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. … [A198807] Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment of COVID-19.

  3. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    It is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.

  4. Drug

    MN-246

    go.drugbank.com/drugs/DB05981
    Experimental

    MN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.

  5. Drug

    Tesmilifene

    go.drugbank.com/drugs/DB04905
    Investigational

    Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast

    Synonyms: N,N-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine
  6. Drug

    Binodenoson

    go.drugbank.com/drugs/DB04853
    Investigational

    Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor. … This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion

  7. Drug

    Insulin-like growth factor II

    go.drugbank.com/drugs/DB14472
    Investigational

    The insulin-like growth factor II is a well-characterized neutral peptide believed to be secreted by the liver and to circulate in the blood. … To perform its biological activities, this growth factor can present some dependence to [somatotropin].

  8. Drug

    GTP-506

    go.drugbank.com/drugs/DB17682
    Experimental

    GTP-506 is a gene therapy formed by two vectors, a nuclease vector targeting gene editing in the well-characterized PCSK9 gene locus and a therapeutic donor vector that inserts the OTC gene to provide

    Synonyms: Non-replicating recombinant adeno-associated virus serotype rh79 (AAVrh.79) vectors: AAVrh79.TBG.M2PCSK9.WPRE.bGH and AAVrh79.hHDR.TBG.hOTCco.bGH
  9. Drug

    Zorecimeran

    go.drugbank.com/drugs/DB15843
    Investigational

    The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. … The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body.

  10. Drug

    CIGB 2020 Vaccine

    go.drugbank.com/drugs/DB15808
    Experimental

    The vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba. … CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered.